{"id":"https://openalex.org/W2260356702","doi":"https://doi.org/10.1200/jco.1994.12.2.402","title":"Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.","display_name":"Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.","publication_year":1994,"publication_date":"1994-02-01","ids":{"openalex":"https://openalex.org/W2260356702","doi":"https://doi.org/10.1200/jco.1994.12.2.402","mag":"2260356702","pmid":"https://pubmed.ncbi.nlm.nih.gov/8113848"},"language":"en","primary_location":{"id":"doi:10.1200/jco.1994.12.2.402","doi":"https://doi.org/10.1200/jco.1994.12.2.402","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1994.12.2.402","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109845825","display_name":"Michael S. Mitchell","orcid":"https://orcid.org/0009-0009-3311-1528","observed_orcids":["https://orcid.org/0009-0009-3311-1528"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]},{"id":"https://openalex.org/I4210117038","display_name":"USC Norris Comprehensive Cancer Center","ror":"https://ror.org/01nmyfr60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800154431","https://openalex.org/I4210117038"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M S Mitchell","raw_affiliation_strings":["Department of Medicine, Norris Comprehensive Cancer Center, University of South California School of Medicine, Los Angeles 90033"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Norris Comprehensive Cancer Center, University of South California School of Medicine, Los Angeles 90033","institution_ids":["https://openalex.org/I1174212","https://openalex.org/I4210117038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009729746","display_name":"James G. Jakowatz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J Jakowatz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063213567","display_name":"William Harel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W Harel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068666680","display_name":"Grace E. Dean","orcid":"https://orcid.org/0000-0002-1951-826X","observed_orcids":["https://orcid.org/0000-0002-1951-826X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G Dean","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039152740","display_name":"Lucy Stevenson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L Stevenson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112013995","display_name":"William D. Boswell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W D Boswell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5067387322","display_name":"Susan G. Groshen","orcid":"https://orcid.org/0000-0001-9705-1012","observed_orcids":["https://orcid.org/0000-0001-9705-1012"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S Groshen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.8045,"has_fulltext":false,"cited_by_count":47,"citation_normalized_percentile":{"value":0.87568896,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"12","issue":"2","first_page":"402","last_page":"411"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.8485999703407288,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.8485999703407288,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.11670000106096268,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0272000003606081,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon-alpha-2b","display_name":"interferon alfa-2b","score":0.9929999709129333},{"id":"https://openalex.org/keywords/active-specific-immunotherapy","display_name":"active specific immunotherapy","score":0.8230000138282776},{"id":"https://openalex.org/keywords/disseminated-melanoma","display_name":"disseminated melanoma","score":0.8690000176429749},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.8700000047683716},{"id":"https://openalex.org/keywords/hla-typing","display_name":"HLA typing","score":0.6710000038146973},{"id":"https://openalex.org/keywords/tumor-associated-antigens","display_name":"tumor-associated antigens","score":0.6480000019073486},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.48899999260902405},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.8199999928474426}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9383631944656372},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6833703517913818},{"id":"https://openalex.org/C2781228144","wikidata":"https://www.wikidata.org/wiki/Q6046441","display_name":"Interferon alfa","level":4,"score":0.6784087419509888},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.5414029359817505},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5317420363426208},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5182933211326599},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.49410179257392883},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.42960041761398315},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.3588172197341919},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.33396363258361816},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.32091253995895386},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.13795587420463562},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014057","descriptor_name":"Tomography, X-Ray Computed","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016233","descriptor_name":"Immunotherapy, Active","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019496","descriptor_name":"Cancer Vaccines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.1994.12.2.402","doi":"https://doi.org/10.1200/jco.1994.12.2.402","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1994.12.2.402","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:8113848","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8113848","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8299999833106995,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G2738109746","display_name":"SPECIFIC ACTIVE IMMUNOTHERAPY OF HUMAN MELANOMA","funder_award_id":"5r01ca036233-10","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G3530951102","display_name":null,"funder_award_id":"CA 36233","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W1488147700","https://openalex.org/W1802347398","https://openalex.org/W1907323769","https://openalex.org/W1973367494","https://openalex.org/W1988645175","https://openalex.org/W2021985978","https://openalex.org/W2077159423","https://openalex.org/W2077329371","https://openalex.org/W2105472774","https://openalex.org/W2106098226","https://openalex.org/W2133514770","https://openalex.org/W2159609881","https://openalex.org/W2239850217","https://openalex.org/W2400831719","https://openalex.org/W2401716101","https://openalex.org/W2412271090"],"related_works":["https://openalex.org/W2130760938","https://openalex.org/W2411438591","https://openalex.org/W7217840980","https://openalex.org/W2073277368","https://openalex.org/W2008263430","https://openalex.org/W1488215556","https://openalex.org/W2343701152","https://openalex.org/W3014244632","https://openalex.org/W2414711602","https://openalex.org/W2396679015"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"determine":[2],"whether":[3],"interferon":[4],"alfa-2b":[5],"(IFN-alfa;":[6],"intron-A,":[7],"Schering":[8],"Corp,":[9],"Kenilworth,":[10],"NJ)":[11],"can":[12],"induce":[13],"a":[14,63,77,113,162,178,201,204],"remission":[15],"in":[16,139,146,174,224,232,249,308],"patients":[17,33,82,127,150,159,228],"previously":[18],"treated":[19,60],"with":[20,34,153,245,255],"active":[21,267],"specific":[22,246,268],"immunotherapy":[23,269],"(therapeutic":[24],"melanoma":[25,36,50,81,256],"vaccine)":[26],"without":[27],"response.":[28,124],"PATIENTS":[29],"AND":[30],"METHODS:":[31],"Eighteen":[32],"disseminated":[35],"who":[37],"had":[38,142,161,203,219],"failed":[39],"to":[40,42,122,243,251],"respond":[41],"at":[43,84,117],"least":[44,85],"five":[45,226,233],"injections":[46],"of":[47,92,102,134,148,157,180,187,208,234,241,266,280,294],"Melacine":[48],"therapeutic":[49],"vaccine":[51],"(Ribi":[52],"ImmunoChem":[53],"Research,":[54],"Inc,":[55],"Hamilton,":[56],"MT)":[57],"were":[58,105,128],"then":[59,116],"IFN-alfa":[61,66,244,271],"after":[62,292],"4-week":[64],"interval.":[65],"5":[67],"or":[68],"6":[69],"x":[70],"10(6)":[71],"U/m2":[72],"was":[73,238],"self-administered":[74],"three":[75],"times":[76],"week":[78],"subcutaneously":[79],"by":[80,168,222,290,297],"for":[83],"2":[86],"months.":[87,182,197,215],"Computed":[88],"tomographic":[89],"(CT)":[90],"scans":[91],"the":[93,103,140,149,188,273,287,295],"chest,":[94],"abdomen,":[95],"and":[96,98,115,194,211,270,283],"pelvis":[97],"magnetic":[99],"resonance":[100],"imaging":[101],"brain":[104],"performed":[106],"within":[107],"4":[108],"weeks":[109],"before":[110,130],"treatment":[111,121,152,300],"as":[112,200],"baseline,":[114],"2-month":[118],"intervals":[119],"during":[120,151],"evaluate":[123],"All":[125],"18":[126,158],"HLA-typed":[129],"treatment.":[131],"The":[132,183,198],"frequency":[133],"cytolytic":[135],"T-cell":[136,217],"precursors":[137,218],"(pCTL)":[138],"blood":[141],"been":[143,192,220],"measured":[144],"weekly":[145],"13":[147],"Melacine.":[154,298],"RESULTS:":[155],"Eight":[156],"(44.4%)":[160],"major":[163],"objective":[164,274],"clinical":[165],"response":[166,242,275],"induced":[167],"IFN-alfa,":[169,291],"including":[170],"site-specific":[171],"complete":[172],"remissions":[173],"five.":[175],"Responses":[176],"lasted":[177],"median":[179,184,205],"11":[181],"survival":[185,206,304],"duration":[186,207],"responders":[189],"has":[190],"not":[191],"reached,":[193],"exceeds":[195],"32":[196],"group":[199],"whole":[202],"10.1":[209],"months,":[210],"nonresponders":[212],"lived":[213],"7.3":[214],"Cytolytic":[216],"increased":[221],"immunization":[223,293],"all":[225],"responding":[227],"tested,":[229],"but":[230],"also":[231],"eight":[235],"nonresponders.":[236],"There":[237],"no":[239],"association":[240],"HLA":[247,281],"phenotypes,":[248],"contrast":[250],"our":[252],"previous":[253],"results":[254],"theraccine":[257],"alone.":[258],"CONCLUSION:":[259],"These":[260],"data":[261],"suggest":[262],"an":[263],"additive":[264],"effect":[265],"on":[272,286],"rate,":[276],"perhaps":[277],"through":[278],"upregulation":[279],"molecules":[282],"tumor-associated":[284],"antigens":[285],"tumor":[288],"cell":[289],"patient":[296],"This":[299],"may":[301],"have":[302],"improved":[303],"over":[305],"that":[306],"expected":[307],"metastatic":[309],"melanoma.":[310]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}